NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Reviewed May 26, 2026

Raloxifene

Prescription ·Strong evidence ·Reviewed May 2026

Raloxifene is a selective estrogen receptor modulator used in postmenopausal women for osteoporosis treatment or prevention and for reduction of invasive breast cancer risk in selected high-risk groups. It improves spine bone density and lowers vertebral fracture risk but increases venous thromboembolism risk and carries a boxed warning for increased risk of venous thromboembolism and death from stroke in women with coronary heart disease or high coronary risk.

What it's good for
  • Treatment of postmenopausal osteoporosis2,1
  • Prevention of postmenopausal osteoporosis2,1
  • Reduced vertebral fracture risk2
  • Reduction of invasive breast cancer risk in selected postmenopausal women1,3
What to watch for
  • Hot flashes
  • Leg cramps
  • Peripheral edema
  • Active or past venous thromboembolism including deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis3,1
  • Pregnancy

The bottom line

Evidence rating strong. Most-documented uses: treatment of postmenopausal osteoporosis, prevention of postmenopausal osteoporosis, reduced vertebral fracture risk. 3 sources indexed (1999–2026), with 4 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Raloxifene acts as an estrogen receptor agonist in bone and lipid metabolism while acting as an antagonist in breast and uterine tissue. In bone, it decreases osteoclast-mediated resorption and turnover, preserving bone mineral density. Its hepatic and coagulation effects contribute to reduced LDL cholesterol but also increased venous thromboembolism risk.2,1

Class
Selective estrogen receptor modulator
Dosing

Dosing & protocol.

Common range
Postmenopausal women: 60 mg orally once daily, with or without food. Ensure adequate calcium and vitamin D intake when dietary intake is insufficient.
Recommended form
Oral tablet once daily

May be taken with or without food. Avoid use during prolonged immobilization and follow label guidance around surgery or immobilization because of clot risk.

Safety

Full safety detail.

Side effects

  • Hot flashes
  • Leg cramps
  • Peripheral edema
  • Flu-like symptoms
  • Arthralgia
  • Venous thromboembolism
  • Retinal vein thrombosis
  • Stroke death risk in high-risk women
  • Gallbladder disease rarely

Contraindications

  • Active or past venous thromboembolism including deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis3,1
  • Pregnancy
  • Breastfeeding
  • Known hypersensitivity to raloxifene1,2
  • Use caution in women with stroke risk, coronary heart disease, prolonged immobilization, or severe hepatic impairment1,2
Interactions

Interaction records.

InfoSynergy

Calcium

Adequate calcium intake supports bone mineralization while raloxifene reduces bone resorption.

Recommendation: Use diet first when possible; supplement only enough to meet recommended intake and avoid excessive calcium.

InfoSynergy

Vitamin D3

Vitamin D sufficiency improves calcium absorption and supports raloxifene-based osteoporosis care.

Recommendation: Correct deficiency and maintain adequate intake; monitor levels when deficiency risk is high.

InfoSynergy

Vitamin K2

Vitamin K2 is sometimes used for bone matrix protein carboxylation and may overlap with bone-health goals.

Recommendation: Use as adjunctive nutrition support only; it does not offset raloxifene clot or stroke risk.

ModerateTiming Sensitive

Psyllium Husk

Large doses of soluble fiber can reduce or delay absorption of some oral drugs and may make raloxifene exposure less predictable.

Recommendation: Separate psyllium from raloxifene by at least 2 hours if both are used daily.

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Randomized controlled trials

2
  • 1Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenNeeds reviewNo linkBarrett-Connor E et al. · New England Journal of Medicine · 2006

    RUTH trial clarified benefit and vascular risk tradeoffs in women with coronary disease or risk factors.

  • 2Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifeneNeeds reviewNo linkEttinger B et al. · JAMA · 1999

    MORE trial data support vertebral fracture reduction and bone density effects.

Reference material

1
Keep exploring

Deep dives & adjacent profiles.

This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.

Use this with your stack

Raloxifene in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.